ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 262 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,060,645 | -11.3% | 146,864 | +1.9% | 0.00% | 0.0% |
| Q2 2023 | $3,450,668 | -51.5% | 144,078 | -61.9% | 0.00% | -66.7% |
| Q1 2023 | $7,116,369 | +42.0% | 378,128 | +20.1% | 0.01% | +100.0% |
| Q4 2022 | $5,012,221 | -19.1% | 314,838 | -16.9% | 0.00% | -25.0% |
| Q3 2022 | $6,197,000 | +39.9% | 378,730 | +20.4% | 0.00% | +33.3% |
| Q2 2022 | $4,430,000 | +58.2% | 314,488 | +171.9% | 0.00% | +50.0% |
| Q1 2022 | $2,800,000 | -45.6% | 115,647 | -47.6% | 0.00% | -33.3% |
| Q4 2021 | $5,151,000 | +36.8% | 220,693 | -2.6% | 0.00% | +50.0% |
| Q3 2021 | $3,764,000 | -11.0% | 226,577 | +30.6% | 0.00% | -33.3% |
| Q2 2021 | $4,231,000 | -15.8% | 173,454 | -10.9% | 0.00% | 0.0% |
| Q1 2021 | $5,024,000 | -42.2% | 194,767 | +19.8% | 0.00% | -40.0% |
| Q4 2020 | $8,691,000 | +74.2% | 162,578 | +34.4% | 0.01% | +25.0% |
| Q3 2020 | $4,990,000 | -67.7% | 120,975 | -62.1% | 0.00% | -69.2% |
| Q2 2020 | $15,470,000 | +109.9% | 319,149 | +83.0% | 0.01% | +85.7% |
| Q1 2020 | $7,369,000 | -22.5% | 174,404 | -21.5% | 0.01% | +16.7% |
| Q4 2019 | $9,506,000 | +20.5% | 222,196 | +1.4% | 0.01% | 0.0% |
| Q3 2019 | $7,886,000 | -13.6% | 219,096 | -35.8% | 0.01% | -14.3% |
| Q2 2019 | $9,126,000 | +94.6% | 341,391 | +95.4% | 0.01% | +40.0% |
| Q1 2019 | $4,690,000 | -65.2% | 174,714 | -79.0% | 0.01% | -64.3% |
| Q4 2018 | $13,481,000 | +76.3% | 833,704 | +126.4% | 0.01% | +100.0% |
| Q3 2018 | $7,647,000 | +211.1% | 368,278 | +128.7% | 0.01% | +133.3% |
| Q2 2018 | $2,458,000 | -14.1% | 161,029 | +26.5% | 0.00% | 0.0% |
| Q1 2018 | $2,861,000 | -49.8% | 127,309 | -32.7% | 0.00% | -25.0% |
| Q4 2017 | $5,695,000 | +16.1% | 189,131 | +45.3% | 0.00% | +33.3% |
| Q3 2017 | $4,904,000 | -26.6% | 130,205 | -45.7% | 0.00% | -57.1% |
| Q2 2017 | $6,685,000 | -11.3% | 239,725 | +9.3% | 0.01% | 0.0% |
| Q1 2017 | $7,538,000 | -62.3% | 219,263 | -68.4% | 0.01% | -61.1% |
| Q4 2016 | $20,017,000 | +236.7% | 694,066 | +271.4% | 0.02% | +260.0% |
| Q3 2016 | $5,945,000 | +8.9% | 186,878 | +11.1% | 0.01% | 0.0% |
| Q2 2016 | $5,460,000 | -23.3% | 168,191 | -33.9% | 0.01% | -37.5% |
| Q1 2016 | $7,118,000 | +95.4% | 254,550 | +149.1% | 0.01% | +166.7% |
| Q4 2015 | $3,643,000 | +16.7% | 102,199 | +8.2% | 0.00% | +50.0% |
| Q3 2015 | $3,123,000 | +28.0% | 94,452 | +62.2% | 0.00% | -33.3% |
| Q2 2015 | $2,440,000 | -3.5% | 58,249 | -25.0% | 0.00% | +50.0% |
| Q1 2015 | $2,529,000 | +257.7% | 77,616 | +248.5% | 0.00% | +100.0% |
| Q4 2014 | $707,000 | +96.4% | 22,271 | +53.3% | 0.00% | – |
| Q3 2014 | $360,000 | -20.5% | 14,526 | -27.6% | 0.00% | – |
| Q2 2014 | $453,000 | -40.8% | 20,074 | -36.2% | 0.00% | -100.0% |
| Q1 2014 | $765,000 | -54.4% | 31,456 | -53.1% | 0.00% | -50.0% |
| Q4 2013 | $1,677,000 | +92.1% | 67,124 | +111.2% | 0.00% | +100.0% |
| Q3 2013 | $873,000 | +42.0% | 31,777 | -6.2% | 0.00% | 0.0% |
| Q2 2013 | $615,000 | – | 33,885 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |